H-Tyr-Phe-OH-13C9,15N TFA
H-Tyr-Phe-OH-13C9,15N ( (L-Tyrosyl-L-phenylalanine-13C9,15N)) TFA is the 13C- and 15N-labeled H-Tyr-Phe-OH (HY-W011258). H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells.
For research use only. We do not sell to patients.
- Formula: C1113C9H21F3N15NO6
- Molecular Weight:452.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
-
Help & FAQs
Biological Activity
Description
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
Unlabeled CAS 1422973-44-1
-
Molecular Weight 452.31
-
Formula C1113C9H21F3N15NO6
-
SMILES
O=C([15NH][13C@@H]([13CH2][13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1)[13C](O)=O)[C@H](CC2=CC=C(C=C2)O)N.OC(C(F)(F)F)=O
-
Synonyms
L-Tyrosyl-L-phenylalanine-13C9,15N TFA
-
Sequence
Tyr-Phe
-
Sequence Shortening
TF
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Purity & Documentation
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
H-Tyr-Phe-OH-13C9,15N TFA Related Classifications
HY-W011258BS Related Classifications
Powered by Bioz